Altimmune Inc (ALT)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

910 CLOPPER ROAD GAITHERSBURG, MD 20878

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).

Data as of 2021-08-02 07:55:43 -0400
Market Cap348.259 Million Shares Outstanding38.397 Million Avg 30-day Volume1.062 Million
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.11 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.91565 52-week High/Low29.71 / 7.8 Next Earnings Date2021-08-11 Price to Cash FLow (P/CF) -24.625
Data provided by IEX Cloud

Are you looking for this stock instead?

View SEC Filings from ALT instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 1 0.0% 1 (0.06%) 1 (0.06%) 0.0%
Funds Holding: 96 89 7.87% 28 (1.64%) 28 (1.63%) 0.0%
13F shares: 23.82 Million 20.471 Million 16.36% 13.8 Million 12.445 Million 10.89%
% Ownership 64.1176 55.1142 16.34% 37.1473 33.505 10.87%
New Positions: 25 38 -34.21% 7 13 -46.15%
Increased Positions 37 27 37.04% 11 7 57.14%
Closed Positions 15 20 -25.0% 6 13 -53.85%
Reduced Positions 21 16 31.25% 8 6 33.33%
Total Calls 745.31 Thousand 463.149 Thousand 60.92% 257.9 Thousand 95.7 Thousand 169.49%
Total Puts 626.742 Thousand 644.217 Thousand -2.71% 293.6 Thousand 164.9 Thousand 78.05%
PUT/CALL Ratio 0.84 1.39 -39.57% 1.14 1.72 -33.72%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ALT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALT BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GARG VIPIN K PRESIDENT AND CEO

  • Officer
  • Director
298,592 2021-07-30 13

HODGES PHILIP

  • Director
26,579 2021-03-01 4

VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P.

VHCP CO-INVESTMENT HOLDINGS III, LLC

VHCP MANAGEMENT III, LLC

VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.

VHCP CO-INVESTMENT HOLDINGS II, LLC

VHCP MANAGEMENT II, LLC

KOH BONG Y

SHAH NIMISH P

  • 10% Owner
No longer subject to file 2021-02-25 1

ROBERTS M SCOT CHIEF SCIENTIFIC OFFICER

  • Officer
9,876 2021-01-31 1

BROWN WILLIAM MICHAEL CHIEF FINANCIAL OFFICER

  • Officer
16,918 2021-01-31 1

HARRIS MATTHEW SCOTT CHIEF MEDICAL OFFICER

  • Officer
5,037 2021-01-31 2

SCHAFER KLAUS

  • Director
8,900 2020-12-10 4

GILL JOHN

  • Director
11,199 2020-11-30 3

DRUTZ DAVID

  • Director
17,936 2020-11-13 3

PISANO WAYNE

  • Director
8,498 2020-11-12 3

SAYARE MITCHEL

  • Director
26,363 2020-09-24 2

JORKASKY DIANE

  • Director
0 2020-09-24 1

VELOCITY PHARMACEUTICAL HOLDINGS LLC

  • 10% Owner
No longer subject to file 2020-05-14 0

VELOCITY PHARMACEUTICAL HOLDINGS LLC

COLLIER DAVID J

WATSON JAMES F

VELOCITY PHARMA MANAGEMENT, LLC

  • 10% Owner
1,887,250 2019-07-12 0

TASKER SYBIL CHIEF MEDICAL OFFICER

  • Officer
0 2019-06-17 0

NOVARTIS BIOVENTURES LTD

NOVARTIS AG

  • 10% Owner
No longer subject to file 2018-10-02 0

ENRIGHT WILLIAM PRESIDENT AND CEO

  • Officer
  • Director
365,839 2018-05-25 0

TRUFFLE CAPITAL S.A.S.

  • 10% Owner
2,161,802 2018-02-13 0

SCHAFFER DERACE L

  • Director
601,846 2017-12-28 0

HODGES PHILIP

REDMONT VAXN CAPITAL HOLDINGS, LLC

  • Director
0 2017-10-13 4

CZEREPAK ELIZABETH CFO AND EVP CORP. DEVELOPMENT

  • Officer
0 2017-09-22 0

HODGES PHILIP

REDMONT VAXN CAPITAL HOLDINGS, LLC

PARADIGM VENTURE PARTNERS, L.P.

REDMONT VENTURE PARTNERS, INC.

  • Director
  • 10% Owner
0 2017-05-04 0

RUNGE JEFFREY W.

  • Director
197,700 2017-01-20 0

ST PETER STEVEN

  • Director
205,004 2017-01-04 0

MACNEILL PHILIP VP, CFO, TREASURER, SECRETARY

  • Officer
126,346 2016-12-21 0

PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.

FROHLICH PHIL

  • 10% Owner
No longer subject to file 2016-12-07 0

RICHMAN ERIC I

  • Director
908,055 2016-11-22 0

JONES JEFFREY MICHAEL COO

  • Officer
2,544 2015-03-11 0

CHANG LINDA L SVP, CFO & SECRETARY

  • Officer
30,000 2015-01-07 0

MCCLEARY JOEL

  • Director
0 2014-12-31 0

MARKISON BRIAN A

  • Director
0 2014-12-31 0

MORGES WAYNE SVP, REG. AFFAIRS & QUALITY

  • Officer
0 2014-12-08 0

COOK FRANCESCA M SVP, POLICY & GOV'T AFFAIRS

  • Officer
0 2014-12-08 0

KARP JORDAN P SVP, GENERAL COUNSEL

  • Officer
0 2012-12-03 0

FUERST THOMAS RICHARD EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
0 2011-12-01 0

PAPPAJOHN JOHN

  • Director
0 2011-06-23 0

RIDDLE VALERIE D SVP, MEDICAL DIRECTOR

  • Officer
44,436 2011-05-25 0

REINHART CHARLES A. III SVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2010-12-08 0

HEALTHCARE VENTURES VII LP

LAWLOR AUGUSTINE

LITTLECHILD JOHN W

MIRABELLI CHRISTOPHER

WERNER HAROLD R

CAVANAUGH JAMES H

HEALTHCARE PARTNERS VII, L.P.

  • Director
  • 10% Owner
4,253,057 2010-11-03 0

EVNIN LUKE

GALAKATOS NICHOLAS

HENNER DENNIS

STEINMETZ MICHAEL

GADICKE ANSBERT

WHEELER KURT

SIMON NICHOLAS J III

  • 10% Owner
6,347,614 2010-11-03 0

MPM BIOVENTURES III LLC

MPM BIOVENTURES III PARALLEL FUND, L.P.

MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG

MPM BIOVENTURES III L.P.

MPM BIOVENTURES III GP L.P.

MPM BIOVENTURES III-QP L.P.

MPM ASSET MANAGEMENT INVESTORS 2004 BVIII LLC

  • 10% Owner
6,347,614 2010-11-03 0

CAVANAUGH JAMES H

  • Director
  • 10% Owner
0 2010-06-23 0

FUSCO JOAN SVP, OPERATIONS

  • Officer
0 2010-05-06 0

CAMUT CHRISTOPHER C VP, GOV'T CONTRACTS

  • Officer
No longer subject to file 2010-01-21 0

WRIGHT DAVID P PRESIDENT AND CEO

  • Officer
  • Director
399,500 2009-12-11 0

PRICE KEVIN PRESIDENT - PHARMATHENE UK,LTD

  • Officer
0 2009-01-21 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

GARG VIPIN K - Director - Officer PRESIDENT AND CEO

2021-08-02 19:00:47 -0400 2021-07-30 F 3,007 $9.07 d 298,592 direct -0.1026 0.0 1 -0.1026 2

GARG VIPIN K - Director - Officer PRESIDENT AND CEO

2021-07-01 19:01:04 -0400 2021-06-30 F 3,007 $9.85 d 301,599 direct -5.0321 -4.6039 0.0 1 -9.743 3

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ALTIMMUNE INC ALT 2021-08-05 22:15:04 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 21:45:03 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 21:15:03 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 20:45:03 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 20:15:04 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 19:45:04 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 19:15:03 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 18:45:03 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 18:15:03 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 17:45:03 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 17:15:03 UTC -0.5727 0.6527 1400000
ALTIMMUNE INC ALT 2021-08-05 16:45:02 UTC -0.5729 0.6529 1400000
ALTIMMUNE INC ALT 2021-08-05 16:15:03 UTC -0.5729 0.6529 1400000
ALTIMMUNE INC ALT 2021-08-05 15:45:03 UTC -0.5729 0.6529 1400000
ALTIMMUNE INC ALT 2021-08-05 15:15:02 UTC -0.5729 0.6529 1400000
ALTIMMUNE INC ALT 2021-08-05 14:45:02 UTC -0.5729 0.6529 1400000
ALTIMMUNE INC ALT 2021-08-05 14:15:04 UTC -0.5729 0.6529 1400000
ALTIMMUNE INC ALT 2021-08-05 13:45:04 UTC -0.5729 0.6529 1400000
ALTIMMUNE INC ALT 2021-08-05 13:15:03 UTC -0.5729 0.6529 1400000
ALTIMMUNE INC ALT 2021-08-05 12:45:03 UTC -0.5729 0.6529 1300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund ALT -414.0 shares, $-5849.82 2021-03-31 N-PORT
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund ALT -2495.0 shares, $-36102.65 2021-04-30 N-PORT

Elevate your investments